Washburn Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

Washburn Capital Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,830	Closed	-$224K	–	46
2023 Q3	$224K	Sell	1,830 -100	-5%	-$12.7K	0.19%	43
2023 Q2	$245K	Sell	1,930 -575	-23%	-$74.7K	0.2%	41
2023 Q1	$324K	Sell	2,505 -200	-7%	-$26.2K	0.28%	44
2022 Q4	$355K	Sell	2,705 -525	-16%	-$67.8K	0.32%	41
2022 Q3	$378K	Hold	3,230	–	–	0.36%	38
2022 Q2	$380K	Buy	3,230 +1,235	+62%	+$147K	0.33%	43
2022 Q1	$260K	Sell	1,995 -4	-0.2%	-$521	0.17%	57
2021 Q4	$305K	Buy	1,999 +314	+19%	+$48.6K	0.18%	44
2021 Q3	$272K	Buy	+1,685	New	+$284K	0.18%	50

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Washburn Capital Management's IBB Position: Q4 2023 in Review

Washburn Capital Management sold out of iShares Biotechnology ETF (IBB) in Q4 2023, closing a stake of 1,830 shares — an estimated $224K sold.

Washburn Capital Management first reported a position in IBB in Q3 2021 and held it in 9 quarters. The position peaked at $380K in Q2 2022. 872 funds tracked by Wall St. Rank hold IBB as of Q4 2023.

Washburn Capital Management reported no remaining iShares Biotechnology ETF position as of Q4 2023 after selling out during the quarter.
Washburn Capital Management sold 1,830 iShares Biotechnology ETF shares in Q4 2023, an estimated $224K.
Washburn Capital Management first reported a position in iShares Biotechnology ETF in Q3 2021 and held it in 9 quarters.
Washburn Capital Management's iShares Biotechnology ETF position peaked at $380K in Q2 2022.
872 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2023.

Based on Washburn Capital Management's 13F filing for Q4 2023, filed 23 Jan 2024.